Kappa Free Light Chains

Overview

Kappa free light chains (κFLC) measure the concentration of unbound immunoglobulin kappa light chains in serum that are not paired with heavy chains to form intact antibodies. These light chains are produced by plasma cells and B‑cells and are normally present at low levels; an excess reflects abnormal plasma‑cell activity or mismatched light‑ versus heavy‑chain production. Elevated kappa free light chains with an abnormal kappa‑to‑lambda free light‑chain ratio can indicate monoclonal gammopathies such as multiple myeloma, light‑chain amyloidosis, or other plasma‑cell dyscrasias, whereas low levels may occur in certain hypogammaglobulinemic states. Clinically, serum free kappa light chains are used as part of the serum free light‑chain assay to help diagnose, monitor, and risk‑stratify patients with monoclonal‑plasma‑cell disorders.

Clinical Use Cases

  • Evaluating suspected monoclonal gammopathy or plasma‑cell dyscrasia (e.g., multiple myeloma, smoldering myeloma, MGUS).
  • Assessing and monitoring light‑chain‑only myeloma or light‑chain amyloidosis.
  • Calculating the kappa‑to‑lambda free light‑chain ratio to detect clonality and monitor disease response.
  • Supporting risk stratification and prognosis in monoclonal‑protein disorders (e.g., abnormal ratio associated with progression risk).

Specimen Types

  • Serum (primary specimen for serum free light‑chain assay).
  • Plasma (less commonly used; serum is standard).

Measurement Methods

  • Nephelometric or turbidimetric immunoassay using anti‑kappa free light‑chain antibodies (paired with lambda‑chain assay in commercial kits).
  • Automated immunoanalyzer platforms that report kappa free light‑chain level, lambda free light‑chain level, and kappa‑to‑lambda ratio.

Test Preparation and Influencing Factors

  • No fasting required; standard venipuncture into serum‑separator tubes.
  • Renal impairment (especially reduced glomerular filtration) can elevate serum free light‑chain levels regardless of clonality.
  • Active infection or inflammatory states may modestly increase polyclonal free light‑chain production.
  • Treatment‑induced plasma‑cell suppression (e.g., chemotherapy, daratumumab) can reduce kappa‑free light‑chain concentrations.

Synonyms

  • Kappa free light chain (κ FLC).
  • Serum free kappa light chain.
  • Kappa‑free Ig light chain.

Further Reading